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Introduction: Differential diagnosis of thrombotic microangiopathies can be difficult. Atypical hemolytic uremic
syndrome is a rare, life-threatening disease caused by uncontrolled chronic activation of alternative complement
pathway, resulting in microvascular thrombosis, organ ischemia and damage. Prognosis is poor: up to 65 percent
of patients require dialysis or have kidney damage of varying severity or die despite plasma exchange/plasma
infusion treatment.
Case presentation: We describe the case of a 23-year-old woman of Hellenic origin who, after a preeclampsia-induced
premature delivery, developed thrombotic microangiopathy with renal failure, tonicoclonic seizures, anasarca edema and
hypertension. Intensive plasma exchange was initiated twice daily, in parallel to dialysis for one month. Three months
later, our patient was discharged with nondialysis-dependent renal failure and without signs of hemolysis. Three
months after discharge our patient was readmitted with cardiomyopathy (left ventricular ejection fraction of 25 percent)
and signs and symptoms of thrombotic microangiopathy. Our patient was diagnosed with atypical hemolytic uremic
syndrome and was started on eculizumab (a complement inhibitor), which improved clinical and laboratory parameters.
However, a transient pause in treatment resulted in thrombotic microangiopathy relapse, which was rapidly blocked
with reintroduction of eculizumab treatment. During long-term eculizumab treatment, thrombotic microangiopathy
manifestations were inhibited and renal and cardiac function restored, with no need for other invasive treatments.
Conclusions: Establishing the diagnosis of atypical hemolytic uremic syndrome in patients presenting with thrombotic
microangiopathy is challenging since common symptoms are shared with other conditions like Shiga toxin-producing
Escherichia coli hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. The described case illustrates
the complexity and importance of rapid diagnosis in a rare disease and the need for appropriate and specific treatment
for best long-term outcomes.Introduction
Thrombotic microangiopathy (TMA) can be a manifest-
ation of several medical conditions, like connective tissue
diseases, malignancy and posttransplantation. However,
TMA manifestations dominate and characterize diseases
like thrombotic thrombocytopenic purpura (TTP), atypical
hemolytic uremic syndrome (aHUS) and Shiga toxin-* Correspondence: mzavros@mphs.moh.gov.cy
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article, unless otherwise stated.producing Escherichia coli hemolytic uremic syndrome
(STEC-HUS), thus making differential diagnosis of TMA
difficult. Both STEC-HUS and aHUS are characterized by
hemolytic anemia, thrombocytopenia and organ failure.
STEC-HUS is more common in children and is associated
with a prior infection from STEC and presence of Shiga
toxin causing endothelial damage and complement activa-
tion [1]. aHUS is characterized by genetic hyperactivation
of the alternative complement pathway and can present
in both children and adults [2-4]. A genetic mutation
in complement regulatory genes has been identified inntral Ltd. This is an Open Access article distributed under the terms of the
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Dysregulation of the complement system leads to endo-
thelial, neutrophil and platelet activation causing TMA as-
sociated with hemolytic anemia and thrombocytopenia,
which in turn may cause severe organ damage in multiple
vital organs [7]. TTP is another form of TMA associated
with severe ADAMTS13 deficiency. ADAMTS13 is an en-
zyme that cleaves the ultralarge von Willebrand factor
multimers that can form in plasma during shear stress
causing platelet aggregation and thrombosis. Management
of TMA often involves plasma exchange and/or plasma
infusion (PE/PI) in an attempt to remove mutant forms
and restore functional proteins. It seems to be effective in
the management of TTP [8], however, outcomes are still
poor in aHUS and a large percentage of patients still pro-
gresses to end-stage renal disease (ESRD) or die at first
clinical manifestation of TMA [3,5,6,9]. Eculizumab is
a humanized monoclonal antibody that binds to comple-
ment component C5 inhibiting its cleavage to C5a and
C5b, inhibiting complement-mediated TMA in patients
with aHUS [10]. Since its introduction in aHUS treatment,
eculizumab has exhibited improved outcomes compared
to plasma exchange (PE) in prospective clinical trials and
in several published cases [10-15]. Eculizumab has been
approved for the treatment of aHUS and is well tolerated
[5,12,16]. We present the case of a young woman of
Hellenic origin who presented with signs and symptoms
of TMA following a preeclampsia-induced premature de-
livery. Our patient was initially managed with PE and dia-
lysis, but TMA multiorgan manifestations persisted and
improved only upon chronic eculizumab treatment.
Case presentation
A 31-week-pregnant young woman of Hellenic origin (age
23), free of previous medical history, was admitted in
January 2011 for an urgent cesarean section due to pre-
eclampsia presenting with nephrotic-range proteinuria
(7gr/24hrs), increased blood pressure (180/100mmHg)
and edema. Five days post-cesarean section, she presented
hemolytic anemia, thrombocytopenia, renal impairment,
tonicoclonic seizures, and hypertensive crisis. Schistocytes
were detected on her peripheral blood smear, while ele-
vated lactate dehydrogenase (LDH) 3254IU/L (laboratory
normal range (LNR): 208 to 408IU/L), total bilirubin
(TBIL) 4.2mg/dL (LNR: 0.3 to 1.2mg/dL) and serum cre-
atinine 4.9mg/dL (LNR: 0.67 to 1.17mg/dL), as well as de-
creased platelet count (PLT: 40×109/L) (LNR: 150 to
480×109/L) were recorded. Intensive PE treatment was
initiated (twice daily for 22 days), in parallel with dialysis
for volume and uremia control.
Following PE and dialysis her clinical condition transiently
improved (serum creatinine: 2.8mg/dL, LDH: 605IU/L,
PLT: 141×109/L). Approximately four months later, in
June 2011, her renal function deteriorated again (serumcreatinine 8mg/dL) and laboratory investigations showed
hemolytic anemia, thrombocytopenia (PLT: 80×109/L), a
negative Coombs test and detectable ADAMTS13 activity
excluding TTP. Stool samples could not detect Escherichia
coli O157:H7/O104:H4 or Shiga toxin, excluding STEC-
HUS. A kidney biopsy was performed, which revealed
evidence of progressing TMA with excessive neutrophil
infiltrations, capillary loop blockade occlusions and abnor-
mal capillary wall thickening. PE and dialysis were restarted;
however, excessive vomiting and hemorrhagic diarrhea
were added to the TMA clinical manifestations. Our patient
was then started on eculizumab in July 2011, after she was
vaccinated against Neisseria menigitidis. Treatment included
900mg weekly eculizumab for four weeks, followed by one
dose of 1200mg. A six-week interruption of eculizumab
treatment occurred due to drug accessibility. During this
period, our patient was managed with dialysis and eculizumab
was reinstated at 1200mg every two weeks in October 2011.
However, following two doses of eculizumab, our patient pre-
sented with pneumonia (tests for Streptococcus pneumoniae
and Haemophilus influenza were negative), cardiac failure
(left ventricular ejection fraction (LVEF) via transthoracic
echocardiography: 35 to 40 percent; pulmonary hypertension:
right ventricular systolic pressure (RVSP): 47.1mmHg) and
hypertensive crisis. She was treated with antibiotics, diuretics
and antihypertensives, and eculizumab treatment was discon-
tinued again due to our patient’s decision.
During this period, her anemia worsened (hemoglobin
7.5g/dL), her LDH and TBIL increased two-fold (428mg/
dL to 1023mg/dL and 0.7mg/dL to 1.9mg/dL respectively),
her renal function was compromised (creatinine 5.5mg/dL)
and schistocytes were observed on the peripheral blood
smear. Hence, a decision was made to reintroduce chronic
eculizumab treatment, starting with one dose of 900mg,
which was followed by 1200mg every two weeks as a main-
tenance dose. Her creatinine and LDH levels decreased
rapidly to normal ranges while her thrombocytopenia was
also reversed (Figure 1). Until her last follow-up visit on
May 2013, our patient remained on chronic eculizumab
treatment, free of any TMA-related complications (creatin-
ine level, 1.5m/dL). No PE/PI, no dialysis and no blood
transfusions were necessary to maintain normal organ func-
tion. Her serum creatinine levels were stable at 1.5mg/dL,
while her LDH levels and PLT remained stable within nor-
mal ranges. A follow-up transthoracic echocardiography
was performed in December 2012, and another in January
2013 where her cardiac function was stable; her cardiac
function was improved (LVEF: 45 to 50 percent) and her
pulmonary pressure was normalized (RVSP <35mmHg).
Discussion
Differential diagnosis of TMA presenting in an adult can
be very challenging. Similar clinical presentation is shared
by the three most common causes of TMA; aHUS, TTP
Figure 1 Response to eculizumab treatment in a young woman of Hellenic origin who was diagnosed with atypical hemolytic uremic
syndrome following a preeclampsia-induced premature delivery. At admission, laboratory results indicated thrombotic microangiopathy,
acute kidney failure and thrombocytopenia; creatinine level 4.9mg/dL; lactate dehydrogenase 3254IU/L; platelets 40×109/L, with the presence of
schistocytes. Plasmapheresis and dialysis managed to temporarily correct clinical indices, however, following deterioration of her clinical status,
our patient was started on eculizumab, 900mg per week, in July 2011. Her clinical condition started to improve after the first administration
of eculizumab. However, due to drug accessibility, the complete dosing schedule of eculizumab could not be maintained and our patient
presented with pneumonia and cardiac failure and was admitted to the intensive care unit. Due to the persistence of her clinical condition
(thrombocytopenia; platelets 73×109/L, renal failure; creatinine 4.85mg/dL, microangiopathy; lactate dehydrogenase 1024IU/L), eculizumab was
reinstated starting at 900mg followed by 1200mg fortnightly. Clinical and laboratory symptoms of thrombotic microangiopathy started to decline
and our patient achieved normal renal function after administration of the first doses of eculizumab. Our patient remains on 1200mg eculizumab
administered every two weeks and is free of any symptoms of thrombotic microangiopathy.
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tissue disorders, drug use after transplantation, humoral
rejection or malignancy can also complicate the picture. It
has been suggested that identifying severe ADAMTS13
protease deficiency (<5 to 10 percent) is a valid way to
differentiate TTP from aHUS [8,17]. In cases where
ADAMTS13 activity estimation is not available, Coppo
et al. have shown that low platelet count (<30×109/L) and
serum creatinine below 2.26mg/dL is highly associated
with severe ADAMTS13 deficiency and TTP [18]. Add-
itionally, postpartum TMA is mostly associated with
aHUS, while TMA during pregnancy is mostly related se-
vere ADAMTS13 deficiency [19]. STEC-HUS can occur
in adults, but requires an identification of either the bac-
teria producing Shiga toxin or the presence of Shiga toxin.
Complement measurements may not always be useful as a
rather large percentage (64 percent) of patients with
aHUS, have normal complement levels of C3 [20]. Under-
taking genetic screening will not provide an answer rapidly
enough for immediate diagnosis. In our case, genetic test-
ing was not accessible and CH50 was not measured. How-
ever, C3 levels were constantly low, indicating alternative
complement pathway activation and, on relapse, C3 levels
showed further decrease. Furthermore, her serum creatin-
ine at presentation was 4.9mg/dL and PLT 40×109/L,
which did not favor the diagnosis of TTP, while no Shiga
toxin or Shiga toxin-producing bacteria were found, thus
excluding STEC-HUS. Therefore, the diagnosis of aHUS
seemed the most probable in this case.
PE/PI has been extensively used to manage TMAs [3].
However, despite optimum PE/PI treatment, more than
one-third of patients with aHUS become refractory to PE,
develop ESRD or die [11,16]. Thus identifying patients with
aHUS is important for the best long-term patient out-
comes. Eculizumab has been associated with rapid inhib-
ition of complement activity and higher long-term efficacy
in blocking systemic TMA and restoring organ function,
compared to PE in patients with aHUS [15,21,22].
Intensive plasma exchange and dialysis improved our
patient’s condition transiently but failed to preserve
renal function. Our patient’s condition deteriorated fur-
ther with symptoms resulting from hemolytic anemia
and thrombocytopenia, while cardiac and lung function
were also affected. Introduction of eculizumab rapidly
inhibited TMA, improved renal function and restored
normal PLT. However, discontinuation of treatment,
which in the present case occurred twice, may have
hampered the corrective effects of eculizumab. Previous
reports have shown that dose reduction or discontinu-
ation of eculizumab treatment lead to TMA relapse,
which may lead to rapid deterioration of vital organs
[23-25]. Upon restarting eculizumab, the induction dose
of 900mg/week for four weeks, followed by 1200mg on
the fifth week is also recommended for efficaciouscomplement blockade. In the present case, the two doses
given after the sustained treatment break of six weeks may
not have been adequate to block complement, as there
was further progression of renal failure, thrombocytopenia
and elevation of LDH. Our patient developed cardiomyop-
athy (LVEF reduced to 25 percent) and pulmonary hyper-
tension (RVSP of 47.1mmHg) that could be explained by
stunned myocardium. Diuresis for a few days improved
her heart failure symptoms, but echo findings did not im-
prove significantly in follow-up echo studies. Reintroduc-
tion of chronic eculizumab treatment led to TMA control,
followed by remission and dramatic improvement not only
of renal function and blood parameters, but also of echo
findings. The last echocardiographic examination, six
months post-relapse episode, showed significant improve-
ment of cardiac function (LVEF of 45 percent) and rever-
sal of pulmonary hypertension, suggesting that TMA
could have contributed to the impaired cardiac function.
Uncontrolled chronic activation of the alternative com-
plement pathway is the underlying cause of systemic
microvascular thrombosis, leading to organ ischemia and
damage. Eculizumab appears as the treatment of choice
for long-term management of aHUS. An increasing body
of evidence, both from clinical investigations and case re-
ports of patients with variable medical history, indicate
that eculizumab is effective in blocking further progres-
sion of TMA in patients with aHUS [5,13,14].
In the present case of aHUS complicated with multiple
organ damage, sustained eculizumab treatment managed
to rapidly block complement activation, reverse renal
impairment and longitudinally attenuate organ ischemia
and damage. Therefore, it is of great importance to iden-
tify aHUS patients early and rapidly initiate, but also
maintain, eculizumab treatment to avoid unnecessary
complement reactivation that could lead to irreversible
and possibly life-threatening organ damage.
Conclusions
The present report described a rare case of aHUS compli-
cated with multiple organ damage. Establishing the diagno-
sis of aHUS in patients presenting with TMA is challenging
since common symptoms are shared with other condi-
tions like STEC-HUS and TTP. In addition, although
ADAMTS13 activity is key factor for the differential
diagnosis of TMAs, if not available, other indicators, such
as platelet and creatinine levels should be considered, espe-
cially in cases of pregnancy-related TMA. Finally, sustained
eculizumab treatment has managed in our case to rapidly
block complement activation, reverse renal impairment
and longitudinally attenuate organ ischemia and damage,
while PE treatment failed to reverse TMA. Therefore, the
rapid identification of aHUS patients along with initiation
and maintenance of proper treatment are essential for a
favorable outcome in this life-threatening, rare condition.
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